Iterum Therapeutics Files S-1/A Amendment

TL;DR

Iterum Therapeutics filed an S-1/A amendment on 6/26/24. Details on execs & HQ in Dublin.

AI Summary

Iterum Therapeutics plc filed an S-1/A amendment on June 26, 2024, related to its registration statement. The filing indicates the company's principal executive offices are located in Dublin, Ireland, with a business phone number of +353 1 6694820. Corey N. Fishman is listed as President and Chief Executive Officer, with a Chicago address.

Why It Matters

This S-1/A filing is an amendment to a registration statement, which typically relates to the offering or sale of securities. Investors should review the details of the amendment to understand any changes or updates to the company's financial or operational disclosures.

Risk Assessment

Risk Level: medium — Amendments to S-1 filings can signal significant corporate actions or changes in financial strategy, requiring careful investor scrutiny.

Key Numbers

• 333-280045 — SEC File Number (Identifies the specific registration statement)
• 2834 — SIC Code (Industry classification for Pharmaceutical Preparations)

Key Players & Entities

• Iterum Therapeutics plc (company) — Registrant
• June 26, 2024 (date) — Filing date
• Corey N. Fishman (person) — President and Chief Executive Officer
• +353 1 6694820 (phone_number) — Company phone number
• Ireland (location) — Jurisdiction of incorporation

FAQ

Key Financial Figures

• $1.21 — chase Units, at a Subscription Price of $1.21 per whole Unit, each whole Unit consi
• $0.01 — (i) our ordinary shares, nominal value $0.01 per share (the ordinary shares), and (i
• $0.605 — 0.50 Units, at a subscription price of $0.605 per 0.50 Unit (the Subscription Price),
• $100,000 — e expenses of the dealer-manager, up to $100,000. See Plan of Distribution on page 70 of
• $250 million — non-affiliate public float in excess of $250 million and annual revenues in excess of $100 m
• $100 m — illion and annual revenues in excess of $100 million, or a non-affiliate public float
• $700 m — non-affiliate public float in excess of $700 million, each as determined on an annual

Filing Documents

• d821831ds1a.htm (S-1/A) — 628KB
• d821831dex231.htm (EX-23.1) — 3KB
• d821831dexfilingfees.htm (EX-FILING FEES) — 50KB
• g821831g21h43.jpg (GRAPHIC) — 3KB
• g821831g34m59.jpg (GRAPHIC) — 34KB
• 0001193125-24-169204.txt ( ) — 730KB

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS 24

USE OF PROCEEDS

USE OF PROCEEDS 26

DILUTION

DILUTION 27 DIVIDEND POLICY 28 THE RIGHTS OFFERING 29 DESCRIPTION OF UNITS 38 DESCRIPTION OF 1-YEAR WARRANTS 39 DESCRIPTION OF 5-YEAR WARRANTS 41 DESCRIPTION OF SHARE CAPITAL 43 MATERIAL TAX CONSIDERATIONS 59 PLAN OF DISTRIBUTION 70 LEGAL MATTERS 73 EXPERTS 73 WHERE YOU CAN FIND MORE INFORMATION 74 INCORPORATION BY REFERENCE 75 i Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we have filed with the Securities and Exchange Commission (the SEC). The exhibits to the registration statement contain the full text of certain contracts and other important documents we have summarized in this prospectus. Since these summaries may not contain all the information that you may find important in deciding whether to purchase our securities, you should review the full text of these documents. The registration statement and the exhibits can be obtained from the SEC as indicated under the sections entitled Incorporation by Reference and Where You Can Find More Information. You should rely only on the information contained in or incorporated by reference in this prospectus, any accompanying prospectus supplement or in any related free writing prospectus filed by us with the SEC. We have not authorized anyone to provide you with different information. This prospectus and any accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus or such accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful, including under the sanctions laws and regulations of the European Union or the United States of America. You should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and

View Full Filing

View this S-1/A filing on SEC EDGAR